Allegro’s osteoarthritis injectable shock absorbing gel demonstrates preclinical safety
11. Dezember 2024 01:30 ET
|
Allegro NV
Clean systemic toxicity profile and no local side-effects following injection Tiny shock absorbing microparticles support and enhance synovial fluidDesigned as potential first-in-class...
PetVivo to Exhibit Spryng with OsteoCushion™ Technology at the American Association of Equine Practitioners Convention on December 8-10, 2024
26. November 2024 15:00 ET
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, Nov. 26, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of medical devices and biomedical therapeutics for equines and companion animals,...
PetVivo Reports Fiscal Q2 2025 Results
14. November 2024 16:00 ET
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Nov. 14, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading biomedical company delivering innovative therapeutic medical devices for equines and...
PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE SECOND QUARTER ENDED SEPTEMBER 30, 2024
11. November 2024 10:07 ET
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Nov. 11, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical...
PetVivo Engages Another Top Sales Manager, Cindy Gill, for Regional Business Development Manager, as Adoption of Breakthrough Animal MedTech Device Continues to Spread Nationwide
21. Oktober 2024 09:45 ET
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, Oct. 21, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Cindy...
Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson
18. Oktober 2024 09:06 ET
|
Can-Fite BioPharma Ltd.
Data Reported by Can-Fite Veterinary Partner Vetbiolix who already exercised its option for a full license deal worth $325M Ramat Gan, Israel, Oct. 18, 2024 (GLOBE NEWSWIRE) --...
U.S. Osteoarthritis Injectables Market Analysis 2024-2030: Rising Prevalence of Osteoarthritis & Increase in R&D Activities for Injectable Drug Developments Spurs Growth
04. Oktober 2024 05:52 ET
|
Research and Markets
Dublin, Oct. 04, 2024 (GLOBE NEWSWIRE) -- The "U.S. Osteoarthritis Injectables Market Size, Share & Trends Analysis Report by Injection Type (Hyaluronic Acid Injections, Corticosteroids...
Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
26. September 2024 08:30 ET
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
24. September 2024 08:30 ET
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
PetVivo Taps Top Sales Executive, Skylor Walker, for Regional Business Development Manager, as Adoption of Breakthrough Animal MedTech Device Continues to Spread Nationwide
16. September 2024 08:00 ET
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, Sept. 16, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Skylor...